Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and neurological disorders. The company leverages its ExacTcell platform and artificial intelligence to enhance safety and accelerate product development.
Tevogen Bio: Overview
Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, precision T cell therapies. These therapies are designed to treat a range of conditions, including infectious diseases, cancers, and neurological disorders. The company's unique approach engages antigens using naturally occurring T cell receptors, enhancing safety and ensuring that healthy cells remain intact.
Tevogen Bio Technology
Tevogen Bio leverages its ExacTcell technology platform, which focuses on the selection and expansion of naturally occurring, genetically unmodified CD8+ cytotoxic T lymphocytes (CTLs). This technology targets antigens present only on diseased cells, preserving healthy cells from unintended harm. The company's ExacTcell platform allows for the development of highly purified, target-specific CTLs, promising enhanced safety and effective treatment for serious conditions.
TVGN 489: Tevogen Bio's Lead Product
Tevogen Bio's lead product, TVGN 489, is designed to meet the urgent needs of acute-risk COVID-19 patients. TVGN 489 has shown promising results in a proof-of-concept clinical trial, with no reported dose-limiting toxicities or treatment-related adverse events. This investigational therapy retains activity against the dominant JN.1 variant of SARS-CoV-2 and is also being investigated for its potential to address critical unmet needs for long COVID treatment.
Tevogen Bio's Research Initiatives
Tevogen Bio has established a research and development center in Philadelphia to facilitate and expedite product development across oncology, neurology, and virology. The company is also exploring the integration of artificial intelligence through its Tevogen.AI initiative, which aims to enhance target detection and accelerate the overall product development process. Additionally, Tevogen Bio has filed patent applications related to AI-driven T cell target identification and receptor engagement.
Financial Milestones
Tevogen Bio has announced up to $50 million in financing to support and advance its operational objectives. The company has also reported the anticipated elimination of a $94.9 million liability, signifying a strong financial position as it continues its research and development efforts. These financial milestones underscore the company's commitment to bringing innovative and cost-effective T cell therapies to market.